Sonnet biotherapeutics announces topline safety data following successful completion of son-1010 monotherapy dose escalation in phase 1 sb101 trial

The maximum tolerated dose (mtd) of son-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
SONN Ratings Summary
SONN Quant Ranking